These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38834107)

  • 1. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis.
    Jiang J; Li Y; Jiang Q; Jiang Y; Qin H; Li Y
    J Infect; 2024 Aug; 89(2):106190. PubMed ID: 38834107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies.
    Mesfin YM; Blais JE; Kibret KT; Tegegne TK; Cowling BJ; Wu P
    J Antimicrob Chemother; 2024 Sep; 79(9):2119-2131. PubMed ID: 38817046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY
    Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
    Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
    Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
    Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
    Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Zur M; Peselev T; Yanko S; Rotshild V; Matok I
    Antiviral Res; 2024 Jan; 221():105768. PubMed ID: 38056602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
    Jang YR; Oh Y; Kim JY
    J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study.
    Lai FTT; Wang B; Wei C; Chui CSL; Li X; Cheung CL; Wong ICK; Chan EWY; Wan EYF
    Age Ageing; 2024 Aug; 53(8):. PubMed ID: 39141078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19.].
    Kurotschka PK; Ebell MH; Serafini A
    Recenti Prog Med; 2024 Sep; 115(9):399. PubMed ID: 39269352
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral antivirals for COVID-19 among patients with cancer.
    Guermazi D; Arvanitis P; Vieira K; Warner JL; Farmakiotis D
    Support Care Cancer; 2024 Jul; 32(8):496. PubMed ID: 38980433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    Tian F; Chen Z; Feng Q
    J Med Virol; 2023 Apr; 95(4):e28732. PubMed ID: 37183808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: A retrospective observational study.
    Lopez D; Pritchard D; Sanfilippo FM; Kelty E; Page A; Etherton-Beer C; Almeida OP; Preen DB
    Infect Dis Now; 2024 Sep; 54(6):104953. PubMed ID: 38964717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.
    Chang LC; Chen IW; Hung KC
    J Med Virol; 2024 Feb; 96(2):e29464. PubMed ID: 38329167
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia.
    Yii YC; Shih HM; Chen CL; Lai ZL; Hsu YL; Lai CH; Hsueh PR; Cho DY
    Int J Antimicrob Agents; 2024 Jan; 63(1):107020. PubMed ID: 37898365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer.
    Hsu WH; Shiau BW; Tsai YW; Wu JY; Huang PY; Chuang MH; Liu TH; Lai CC; Weng TC
    J Infect Public Health; 2024 Aug; 17(8):102465. PubMed ID: 38878678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes.
    Chagla Z
    Ann Intern Med; 2024 Jan; 177(1):JC7. PubMed ID: 38163374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.